Salvatore Alfieri, Rebecca Romanò, Sara Marceglia, Vincenzo De Giorgi, Ketty Peris, Pietro Sollena, Alfredo Piccerillo, Ruggero Moro, Giulio Gualdi, Paolo Antonio Ascierto, Marco Palla, Miriam Paone, Laura Eibenschutz, Francesco Spagnolo, Paola Queirolo, Daria Maria Filippini, Stefano Cavalieri, Carlo Resteghini, Cristiana Bergamini, Antonello Manocchio, Lisa Licitra, Paolo Bossi
INTRODUCTION: In advanced basal cell carcinoma (BCC), the issue of whether Hedgehog inhibitors (HHIs) should be stopped or not after clinical complete response (cCR) achievement remains an unmet clinical need. MATERIALS AND METHODS: We conducted a retrospective, multicenter study across 7 Italian dermato-oncology units including patients with BCC who continued vismodegib after cCR between 2012 and 2019. We assessed the relationship between the duration of vismodegib intake (days to cCR [DTCR], days to stop after cCR [DTS], total treatment days [TTD]), and disease-free survival (DFS)...
December 21, 2023: Oncologist